<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4676">
  <stage>Registered</stage>
  <submitdate>17/10/2014</submitdate>
  <approvaldate>17/10/2014</approvaldate>
  <nctid>NCT02275923</nctid>
  <trial_identification>
    <studytitle>Reveal LINQ Evaluation of Fluid</studytitle>
    <scientifictitle>Reveal LINQ Evaluation of Fluid</scientifictitle>
    <utrn />
    <trialacronym>REEF</trialacronym>
    <secondaryid>REEF</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>End Stage Renal Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - Reveal LINQ Insertable Cardiac Monitor

Experimental: Diagnostic - 'Reveal LINQ Insertable Cardiac Monitor' will be used to measure changes in subject subcutaneous impedance and compare with the fluid status assessed by the volume removed from the hemodialysis subject during dialysis sessions.


Treatment: devices: Reveal LINQ Insertable Cardiac Monitor
Insertable cardiac monitor

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome> Slope of the regression line between fluid volume and subcutaneous impedance - The linear association between fluid volume removal during the dialysis and change in subcutaneous impedance for dialysis sessions occurring from day 7 to day 30 after implant.</outcome>
      <timepoint>24 Days</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Patients who currently undergo in-clinic hemodialysis treatment prescribed 2 or 3
             times per week

          -  Patients willing to be implanted with the Reveal LINQ device

          -  Patients greater than 21 years of age

          -  Patients willing and able to comply with the study procedures including giving
             informed consent</inclusivecriteria>
    <inclusiveminage>21</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Patient has an active implanted cardiac medical device (e.g. IPG, ICD, CRT, etc)

          -  Patients who currently undergo home dialysis treatment

          -  Patient is enrolled in another study that could confound the results of this study,
             without documented pre-approval from a Medtronic study manager.

          -  Patient with a recent infection defined as 1) bacteremia within 60 days OR 2)
             (nonbacteremic) infection within 14 days

          -  Patient not suitable for Reveal LINQ implantation (e.g., severe cachexia,
             dermatologic conditions of the skin, or major medical or social conditions expected to
             reduce survival to &lt; 6 months), in the opinion of the investigator</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Diagnosis</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>70</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Unknown status</recruitmentstatus>
    <anticipatedlastvisitdate>1/10/2015</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>The Alfred Hospital - Melbourne</hospital>
    <postcode>3004 - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Medtronic Cardiac Rhythm and Heart Failure</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to investigate the use of subcutaneous impedance measured with
      an implanted Medtronic Reveal LINQ insertable cardiac monitor for use as a fluid status
      monitor in hemodialysis patients. The study will measure the changes in subject subcutaneous
      impedance and compare with the fluid status assessed by the volume removed from the
      hemodialysis subject during dialysis sessions. Subcutaneous impedance trends will also be
      evaluated between dialysis sessions.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02275923</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Jennifer Seamans</name>
      <address />
      <phone>763-526-2835</phone>
      <fax />
      <email>jennifer.l.seamans@medtronic.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>